The pharmacological effects of benzodiazepines are thought to be mediated by specific brain re ceptors Braestrup et aI. , 1977) , alterations of which have been suggested in anxiety disorders, epilepsy, ethanol dependence (Chugani and Olsen, 1986) , and hepatic encepha lopathy (Samson et aI. , 1987) and demonstrated in Huntington's disease postmortem (Trifiletti et aI. , 1987) . The benzodiazepine receptors in brain have been studied in vivo with PET in baboons and humans (Comar et aI. , 1979; Maziere et aI. , 1983; Hantraye et aI. , 1984; Samson et aI. , 1985; Persson et aI. , 1985; Shinotoh et aI. , 1986; Frost et aI. , 1986) . These studies have shown that the ll C-Ia beled antagonist RO 15 1788 possesses most of the favorable characteristics necessary to allow optimal investigation of the benzodiazepine receptors' binding variables in vivo, among which are a high 304 ally in a single PET study is proposed, using the data from the full-saturation studies as a stable estimate of the nondisplaceable radioligand concentration. Using this method, it was found that quasiequilibrium between the estimated specifically bound and nondisplaceable compo nents was achieved at times equal to or longer than 20 min after tracer administration. The validity of this method was partly supported by further results, showing a good agreement between the regional specific binding so calculated and postmortem data of receptor density.
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blood-brain barrier permeability, a very high spe cific/nonspecific binding ratio, and a high affinity and selectivity for central type benzodiazepine re ceptors. In addition, all the criteria necessary for demonstration of in vivo specific binding have been obtained for this ligand in previous rat, baboon, and human studies (Maziere et aI. , 1983; Goeders and Kuhar, 1985; Hantraye et aI. , 1984; Samson et aI. , 1985) . Finally, although the rapid appearance of la beled metabolites in blood after the i. v. injection of 11 C_ RO 15 1788 may complicate the design of a ki netic quantitative model (Perlmutter et aI. , 1986) , it has been shown that radioactivity in rat brain tissue 30 min after injection is almost exclusively in the form of unchanged RO 15 1788 (Inoue et aI. , 1985) .
The lack of adverse effects of RO 15 1788, even at very large doses (Darragh et aI. , 1983) , makes this drug a ligand of choice to perform saturation and displacement experiments in humans. In this study, we report in detail the brain regional kinetics of total, specifically bound, and nondisplaceable ll C _ RO 15 1788 obtained by positron emission to mography (PET) in 17 healthy volunteers; in nine, saturation experiments at varying doses have been performed. Based on the evidence from the results, we propose a simple method to estimate from a single standard study the brain region's specific binding of IlC-RO 15 1788.
MATERIALS AND METHODS
Seventeen healthy human volunteers were studied: all but one were male. Their ages ranged from 23 to 73 years with a mean of 40 ± 16. They had not taken any medica tion for at least 2 weeks before the PET study, and they had never used benzodiazepine drugs regularly.
The RO 15 1788 was labeled with high specific radioac tivity by carbon-Il, using the methylation process de scribed previously (Maziere et aI., 1984) . The PET studies were performed using the LET! time-of-flight positron camera , which provides seven slices simultaneously (four direct and three crossed slices). The axial and the lateral resolutions were both 12-mm FWHM (full width at half maximum using me dium-resolution shadow shields) with an undetected in terslice space of about 3 mm. The correction for attenua tion was performed by means of 68Ge_68Ga transmission scans. All subjects were studied at rest, with ey es closed and ears unblocked. The head was carefully positioned in a head-holder by means of a crossed laser-beam system so that the center of the lowest slice was -1 cm above the orbitomeatal line. The cerebral radioactivity data were acquired for 65 min following the i.v. bolus injection of 19.5 ± 7.4 mCi of lIC-RO 15 1788. A total of 31 serial scans for each brain level was collected, the acquisition time being expanded progressively from 1 to 10 min to allow roughly similar statistical counts in each image. Correction for lIC decay was automatically obtained in acquisition data. A total of 16 venous blood samples were collected during the study, ten during the first 10 min and then every 10 min until the end of the study to obtain a whole-blood radioactivity concentration time-course (un corrected for metabolites).
In eight subjects (controls), the experiments were per formed after injection of trace doses of lIC-RO 15 1788 (9.5-106 nmol), the specific radioactivity varying be tween 106 and 2,000 mCiifLmol (mean, 864 ± 630). In the remaining nine subjects, studies at higher doses of RO 15 1788 were performed, a varying amount of unlabeled drug (from 400 to 79,000 nmol) being co-injected with the la beled tracer, resulting in a decrease of the specific radio activity (range, 58-0.34 mCilfLmol). In these "inhibi tion" or "saturation" experiments, 21 serial scans were obtained instead of 31; because of lower count rates, ac quisition time of the late sequences was increased with respect to the control studies to improve the counting statistics. No pharmacological effects were observed even at the highest injected doses of RO 15 1788.
Data analysis
Circular regions of interest (area, 3 cm2) were placed according to a standardized method (Samson et al., 1986) in the occipital, frontal, inferior temporal, and temporo parietal cortices, in the cerebellum, and in white matter.
For each plane of study, the early image (t = 2 min), which represents essentially the perfusion-dependent dis tribution of tracer (Samson et al., 1985) , was chosen for region of interest determination; the position of the re gions of interest was based on the PET atlas of Mazziotta et al. (l981a) since it has been demonstrated that local perfusion and glucose utilization are tightly coupled in normal human brain (Baron et al., 1984) . The regional brain activity so determined for each sequential scan and expressed as a percentage of the injected dose per 1,000 ml of tissue (%ID), was plotted versus time. The brain regional kinetics of lIC-RO 15 1788 were therefore ob tained for each subject. The blood radioactivity was simi larly expressed as %ID. When necessary, the results have been expressed in molar drug concentration by using the specific radioactivity values.
RESULTS

Control studies
After the injection of trace doses of IlC-RO 15 1788, there was a rapid rise of brain radioactivity, the maximum uptake being reached within 8 min, earlier in white matter and cerebellum than in cere bral cortex (Fig. 1) . At peak the mean uptake was highest in the cerebral cortex, intermediate in infe rior temporal lobe and cerebellum, and lowest in white matter. The peak was followed by a gradual decrease which was faster in the cerebellum than in cerebral cortex (Fig. 1) .
In controls, the venous blood kinetics of l 1 C-RO 15 1788 were identical to previously published data (Samson et aI., 1985; Shinotoh et aI., 1986) , showing a peak at 1-2 min after injection followed first by a rapid decline and then by a slight increase between 5 and 10 min-followed by a gradual de cline until the end of the study. The blood radioac tivity was highly variable among different subjects at early times, but it was more reproducible after 20 min.
Saturation experiments
The venous blood kinetics measured in satura tion experiments were not significantly different from control studies (t test comparison). The co-in jection of increasing amounts of unlabeled RO 15 1788 reduced the initial uptake and accelerated the clearance of IlC-RO 15 1788 in a dose-dependent mode. For example, the uptake of IlC-RO 15 1788 in the occipital cortex at 20 min was 89%, 69%, 48%, 32%, and 27% of the mean control values for cold drug doses of 0.0016, 0.003, 0.007, 0.01, and 0.02 mg/kg, respectively (Fig. 2) .
With co-injected drug amounts above 0.1 mg/kg (about 26,000 nmol), there was no further decre ment of the brain radiotracer kinetics after about the 20th min (Table 1) . For example, the radioactive concentration in the occipital cortex at 20 min was 14%, 14%, 16%, and 11% of mean control values for injected drug amounts of 0.1, 0.17, 0.2, and 0.3 mg/kg, respectively (Fig. 2 ). These observations suggest that saturation of the specific binding sites was consistently achieved; similar effects were ob- To clarify the graph, the SOs are not shown; the coeffi cients of variation ranged from 14% (cerebellum) to 24% (white matter) at t = 10 min and from 10% (cerebellum) to 31% (white matter) at t = 30 min.
tained in the remaining brain regions that were ana lyzed (Table O .
Determination of nondisplaceable and specifically bound llC-RO 15 1788
Among the four full-saturation studies, there was little variability of brain tracer concentration in each gray matter structure at each time (�20 min), with a coefficient of variation ranging from 11.8 to 26.3% (mean, 16.8%) ( Table 2 ). This allows us to average these full-saturation data to obtain mean time-activity curves as a representation of the re gional nondisplaceable tracer kinetics. For ex- ample, the nondisplaceable fraction calculated in this way for the t = 30 min data represents 14%, 15%, 14%,4 1%, and 24% of the corresponding con trol values shown in Ta ble 1 in the occipital, frontal, temporoparietal cortex, white matter, and cere bellum, respectively. Knowing this nondisplaceable fraction, it becomes possible to estimate the average kinetics of the specifically bound llC-RO 15 1788 for each brain region. This can be done by simply subtracting the mean nondisplaceable ki netics from the corresponding mean control ki netics (n = 8) according to the simple equation where B is the specifically bound ligand, T is the total raw kinetics in controls, and ND is the non displaceable radioligand concentration. The re sulting specific binding kinetics are shown in Fig. 3 . The time-course of the specifically bound/nondis placeable ratio for each of four gray matter struc tures is shown in Fig. 4 . These values were ob tained by first calculating the specifically bound/ nondisplaceable ratio kinetics in each of the eight control studies by applying, on an individual basis, Eq. 1 and then by averaging the data. After a slow rise lasting about 20 min, the specifically bound/ nondisplaceable kinetics reached an essentially constant value, suggesting a state of quasiequili brium between nondisplaceable and specifically bound ligands at times �20 min. The regional spe cifically bound/nondisplaceable plateau value was higher in the occipital, frontal, and inferior tem poral cortices than in cerebellum. The specifically bound radioligand was also determined individually for each of the five partial-saturation coinjection studies (443-4750 nmol of RO 15 1788), using the above procedure (Eq. 1). If the mean value of spe cifically bound ligand calculated in the eight control studies is taken to represent 100% specific binding (acknowledging the inherent variability in specifi cally bound ligand among different subjects), the plot of the percentage of specific binding (%B ob tained in the five partial-saturation studies) versus the amount of co-injected RO 15 1788 consistently showed typical inhibition patterns. As an example, Fig. 5 shows the resulting sigmoid-shaped curve obtained in the occipital cortex at t = 20 min. The plots of total and specifically bound radioligand (expressed in molar concentration) versus injected RO 15 1788 consistently showed typical hyperbolic patterns. As an example, the resulting curves for the occipital cortex (20-min data) are presented in Fig. 6 . Since the nonspecific binding of RO 15 1788 in vivo is considered negligible (Goeders and Kuhar, 1985) , the nondisplaceable tracer in brain can be taken to represent almost exclusively the free li gand concentration. This consideration suggested an approach to examine the relationships between specifically bound and free ligand in order to test further the validity of our method of estimation of specifically bound. The curves of specifically bound (expressed as percentage of control) as a function of free ligand were typical for inhibition experiments, as shown in Fig. 7 (occipital cortex) . The plots of total and specifically bound (expressed in molar concentration) as a function of free ligand were also characteristic for all times examined (see Fig. 8 for illustration). Scatchard plots (specifically bound/free ligand versus specifically bound) of these data consistently provided statistically signifi cant linear regressions, allowing us to obtain sepa rately the Kd and the Bmax values for the occipital, frontal, and inferior temporal cortices and for the cerebellum (20-, 30-, 40-, and 50-min data; Ta ble 3). Using the inhibition curves obtained earlier ( Values are expressed in percentages of injected dose per 1,000 ml brain tissue.
• OCCIPITAL CORTEX Shinotoh et aI., 1986) . Particularly, our data demonstrate that this radioligand has easy access to brain tissue followed by a rapid redistribution in favor of the gray matter structures that contain the highest density of cen tral type benzodiazepine receptors (Fig. 1) matter, with intermediate effects in the cerebellum -a rank order compatible with known regional dif ferences in human brain benzodiazepine receptor density (Braestrup and Nielsen, 1983; Whitehouse et aI. , 1985; Trifiletti et aI. , 1987) . The apparent presence of displaceable tracer (albeit only as a small amount) in white matter is, however, incon sistent with the well-known lack of central type benzodiazepine receptors in this structure (Braes trup and Nielsen, 1983) . We interpret this discrep ancy as due to the ill effects of partial voluming in PET studies (Mazziotta et aI. , 1981b) , which would
O �------'--------.--------r--------r------�--------'-
artifactually include some gray matter radioactivity in the region of interest localized in the centrum semiovale.
An interesting fact that emerged from these studies was that apparently full prevention of llC _ RO 15 1788 specific binding was achieved for doses of co-injected RO 15 1788 above 0. 1 mg/kg (Fig. 2) ; although the subject who received the highest dose of cold drug had a slightly lower brain %ID of l l C _ RO 15 1788 (Table 1) , there was no consistently sig nificant relationship between the dose of cold drug and the %ID across all regions and all times over 20 min in these four studies. These observations sug gest that a simple method to estimate from a single study the specifically bound llC-RO 15 1788 in in dividual brain regions could be at hand. This method, based on the fact that the measured non displaceable ligand fraction was quite consistent (at times �20 min) among the four fully saturated sub jects (see Ta ble 1), consists of subtracting, for each time and each region, the nondisplaceable fraction from the total llC-RO 15 1788 activity: displace able = total (measured) -nondisplaceable (esti mated).
The regional kinetics of specifically bound li gand estimated in this way (Fig. 3) are compatible with the distribution of central type benzodiazepine receptors reported in vitro (human brain post mortem), with the highest binding in cortical struc tures and lower binding in cerebellum (with the ex ception of white matter, as discussed above).
More complex methods to estimate specifically bound ligand in human brain with PET have em- FIG. 6 . Total and specifically bound ll C _ RO 15 1788 concentration (calculated as the %ID times the total injected drug amount in nanomoles) as a function of the injected drug amount in the occipital cortex at 20 min. The values found in the eight control studies are shown here as means ± SD. The remaining data were extracted from the five partial satu ration co-injection studies. ployed paired studies in the same subject, one being at full saturation to measure the nondisplace able ligand (Shinotoh et aI., 1986) , an approach sim ilar to that used in receptor autoradiography in vitro. However, this entails two PET studies in the same person, which may cause serious difficulties (e.g., head repositioning, patient cooperation, ra diochemistry). A different approach would be to use a reference brain structure known to lack spe cific benzodiazepine receptors as an internal stan dard for nondisplaceable ligand (blank), in a way similar to the dopamine receptor PET studies (Wong et al., 1984; Maziere et al., 1985; Farde et al., 1986; Baron et al., 1986) . White matter could be used in principle for this purpose (Persson et aI., 1987) ; unfortunately, due to inadequate spatial res olution of present PET systems, the radioactivity in this structure is contaminated by counts from gray matter and does not purely represent nondisplace able radioligand. In addition, this approach would assume that the nondisplaceable fraction is iden tical in the reference and assessed structures. A third approach would be to displace the specifically bound l IC-RO 15 1788 by fully saturating doses of the unlabeled compound near the end of the study and then extrapolating the nondisplaceable fraction back to the time chosen for measurement of specifi cally bound ligand. This method, however, would need to be validated on its own merits. A fourth and final possibility would be to use the blood ra dioactivity data to estimate the nondisplaceable li gand concentration in brain tissue (Ciliax et al., 1986; Inoue et al., 1985) . However, it has been demonstrated that radioactive metabolites appear Vol. 8, No.3, 1988 in blood within 5 -1 0 min after i. v. injection of ll C _ RO 15 1788 in humans and may amount to 60% of total blood radioactivity at 20 min (Shinotoh et al., 1986) ; these metabolites, which apparently do not cross the blood-brain barrier (Inoue et al., 1985) , would therefore need to be measured in each study, a complex procedure (Shinotoh et al., 1986) , or else they would have to be assumed to be constant among different subjects and conditions. U sing our method, we found that a state of phar macological quasi equilibrium between specifically bound and nondisplaceable ligand was achieved during the PET study, as demonstrated by the fact that the specifically bound/nondisplaceable ratio reached a plateau value at times over 20 min (Fig .  4) . This allowed us to investigate the validity of our method of measurement of specifically bound li gand by constructing inhibition and saturation curves. Expected pharmacological features, such as the sigmoid-shaped inhibition of specifically bound ligand as a function of the co-injected drug amount (Fig. 5) and typical hyperbolar total and specifically bound molar concentration curves as a function of co-injected drug amount, were obtained (Fig. 6) , supporting the reliability of the method.
We sought additional confirmation by analyzing our data further. On the basis of previous in vitro and in vivo animal experiments (Brown and Martin, 1984; Inoue et al., 1985; Goeders and Kuhar, 1985; Gossuin et al., 1986) , it seemed reasonable to as sume that the nonspecific binding of RO 15 1788 is negligible. This assumption allowed us to consider the nondisplaceable fraction as the free ligand con centration. This in turn led to constructing inhibi tion and saturation curves of specifically bound as a function of free ligand, which displayed typical pharmacological features (Figs. 7 and 8 ). Scatchard analysis of these data showed a moderate but clear cut decrease of the calculated Bmax and Kd values with increasing times of determination (Table 3) .
This dependency on time is difficult to explain, but it might result either from lack of complete pharma cological equilibrium of the ligand-receptor interac tion within the time allowed by the use of l IC (a modest decline in the specifically bound/nondis placeable ratio between 20 and 60 min can be seen in Fig. 4) or from a gradual, dose-dependent ap pearance in brain tissue of labeled inactive metabo lites, although the latter has not been reported to date (Inoue et al., 1985) . Additional possible causes for this unstability of calculated Bmax and Kd may have resulted from the use of different subjects; al though the effects of age are probably minimal (we found that the specifically bound/free ligand ratio was independant of age in our small population of Mean ± SD 41.6 ± 12.2 6.8 ± 1.5 33.8 ± 9.4 6.2 ± 1.5 22.4 ± 9.2 4.6 ± 2.3 20.4 ± 8.5 6.1 ± 2.0 a Linear regression not significant. controls), the small variability in the positioning of the region of interest may have played a role (it is worthy of note that the Bmax/Kd ratio calculated by our method shows only little dependency on time of measurement). Despite these considerations, both the regional distribution and the range and mean of the Bmax and Kd values found here are consistent with those measured in vitro with tritiated RO 15 1788 in human brain postmortem (Whitehouse et aI. , 1985; Tr ifiletti et aI. , 1987) at physiological tem peratures (Mohler and Richards, 1981) . It must be said, however, that the assumption of negligible nonspecific binding, if untrue, may have resulted in overestimation of free ligand and, in turn, in an un derestimation of Bmax. We want to stress, how ever, that the Bmax and Kd values reported here should not be taken as definitive data but as products of the strategy chosen to validate the pro posed method. On the whole, therefore, the results presented in dicate that our approach for estimation of regional specifically bound ligand from a single PET study is reasonably accurate (acknowledging the small vari ability in brain llC_ RO 15 1788 kinetic measured in controls; Fig. 1 and Ta ble 1), although it will be nec essary to determine the nondisplaceable fraction in each population if application in pathology is con templated. The determination of the specifically bound/free ligand ratio at equilibrium in any given brain region is of particular interest as it reliably reflects the Bmax/Kd ratio when free ligand is negli gible relative to Kd (in our conditions of high spe cific radioactivity, the estimated free ligand/Kd ratio in control studies was about 5%). In this situation, the classic equilibrium equation specifically bound/ free ligand = Bmax/(Kd + free ligand) simplifies to specifically bound/free ligand = Bmax/Kd' the "binding potential" (Mintun et aI. , 1984) . It is rele vant to this comment that the distribution of the re gional specifically bound/free ligand values found here (Fig. 4) are consistent with in vitro receptor regional densities in human brain (Braestrup and J Cereb Blood Flow Metab, Vol. 8, No.3, 1988 Nielsen, 1983; Whitehouse et aI. , 1985; Tr ifiletti et aI., 1987) .
